Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.
August 2026 | Volume 19 | No 3
To sign up for our newsletter or print publications, please enter your contact information below.